Business Description
Anebulo Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0345691036
Description
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.77 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 48 | |||||
| 3-Year EPS without NRI Growth Rate | 28.5 | |||||
| 3-Year FCF Growth Rate | 4.4 | |||||
| 3-Year Book Growth Rate | -45.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -25.55 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.18 | |||||
| 9-Day RSI | 27.17 | |||||
| 14-Day RSI | 31.23 | |||||
| 6-1 Month Momentum % | -48.55 | |||||
| 12-1 Month Momentum % | -19.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.45 | |||||
| Quick Ratio | 3.45 | |||||
| Cash Ratio | 2.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -155.24 | |||||
| ROA % | -136.18 | |||||
| ROIC % | -1252.43 | |||||
| ROC (Joel Greenblatt) % | -5039.87 | |||||
| ROCE % | -151.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 22.19 | |||||
| Price-to-Tangible-Book | 21.8 | |||||
| EV-to-EBIT | -4.02 | |||||
| EV-to-EBITDA | -4.02 | |||||
| EV-to-FCF | -4.4 | |||||
| Price-to-Net-Current-Asset-Value | 36.33 | |||||
| Price-to-Net-Cash | 54.5 | |||||
| Earnings Yield (Greenblatt) % | -24.88 | |||||
| FCF Yield % | -16.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anebulo Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.274 | ||
| Beta | 0.11 | ||
| Volatility % | 45.76 | ||
| 14-Day RSI | 31.23 | ||
| 14-Day ATR (€) | 0.066981 | ||
| 20-Day SMA (€) | 1.3265 | ||
| 12-1 Month Momentum % | -19.32 | ||
| 52-Week Range (€) | 1.04 - 2.88 | ||
| Shares Outstanding (Mil) | 41.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anebulo Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anebulo Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Anebulo Pharmaceuticals Inc Frequently Asked Questions
What is Anebulo Pharmaceuticals Inc(FRA:214)'s stock price today?
The current price of FRA:214 is €1.09. The 52 week high of FRA:214 is €2.88 and 52 week low is €1.04.
When is next earnings date of Anebulo Pharmaceuticals Inc(FRA:214)?
The next earnings date of Anebulo Pharmaceuticals Inc(FRA:214) is 2025-02-13 Est..
Does Anebulo Pharmaceuticals Inc(FRA:214) pay dividends? If so, how much?
Anebulo Pharmaceuticals Inc(FRA:214) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers